FindTrial
Sign In

A real-world study of first-line maintenance therapy with senaparib in newly diagnosed advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer

A real-world study of first-line maintenance therapy with senaparib in newly diagnosed advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127770
Enrollment
Unknown
Registered
2026-07-07
Start date
2026-07-07
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First-line maintenance therapy in newly diagnosed advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer patients

Interventions

Senaparib Group:None

Sponsors

The First Affiliated Hospital Of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients newly diagnosed with advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer; 2. aged >=18 years; 3. assessed by the investigator as eligible for treatment with the sunitinib regimen; 4. and willing to participate in this study;

Exclusion criteria

Exclusion criteria: 1.Women who are confirmed to be pregnant or breastfeeding; 2.situations where the researchers determine that they are otherwise not suitable for inclusion in the study;

Design outcomes

Primary

MeasureTime frame
Safety;—

Secondary

MeasureTime frame
Overall survival, OS;Progression Free Survival, PFS;—

Countries

China

Contacts

Public ContactWei Ye

The First Affiliated Hospital Of Anhui Medical University

251498339@qq.com+86 551 63633742

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026